Financings in Brief: Lifecore Biomedical
This article was originally published in The Gray Sheet
Lifecore Biomedical: Raises about $20 mil. in net proceeds from secondary offering of 2.2 mil. shares at $9.75 each. Lifecore filed a registration statement for the offering in August ("The Gray Sheet" Sept. 4, p. 9). About 2 mil. shares in the offering were handled by Piper Jaffray and Needham & Co. while roughly 200,000 shares were acquired by Johnson & Johnson Development Corporation. After the offering, Lifecore has about 10.2 mil. shares outstanding, with J&J holding an approximately 9.5% stake...
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.